SEC Filing Analysis: Revolution Medicines, Inc.

Executive Summary

• Trading Significance: Low
• Key Takeaway: Routine disposition of RSU-derived shares under a 10b5-1 plan adopted in 2023.
• Market Impact: Neutral; transaction size is immaterial to market capitalization.

Company Information

Field	Value
Company	Revolution Medicines, Inc.
CIK	0001628171
Industry	Biological Products

Insider Information

Field	Value
Name	Kelsey Stephen Michael
Title/Position	Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	144 (Notice of Proposed Sale)
Transaction Date	2026-03-16 (Approx)
Transaction Code	S (Proposed)
Security Type	Common Stock
Shares Involved	3,901
Price Per Share	~$99.59 (Implied)
Total Value	$388,500.59
Shares Owned After	Not Disclosed on Form 144

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$388,500.59
% of Market Cap	~0.002%
Shares Transacted	3,901
% of Shares Outstanding	~0.002%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market cap of $19.69 billion, a $388k transaction is statistically negligible.
• Transaction Significance: The shares represent approximately 0.002% of the 193.3M shares outstanding, indicating no control-shifting or sentiment-driving volume.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is small, pre-planned (10b5-1), and relates to the vesting of Restricted Stock Units (RSUs) from 2022-2025. It does not signal a lack of confidence.

Volume & Sentiment

• Expected Volume Impact: None.
• Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

• Source of Shares: Shares were acquired via RSU grants vesting between 2022 and 2025.
• 10b5-1 Plan: The sale is being conducted under a Rule 10b5-1 trading plan adopted on May 31, 2023, nearly three years prior to this filing.